Zacks: Analysts Anticipate EXACT Sciences Co. (EXAS) Will Announce Earnings of -$0.42 Per Share
Analysts predict that EXACT Sciences Co. (NASDAQ:EXAS) will announce earnings per share of ($0.42) for the current quarter, Zacks reports. Five analysts have made estimates for EXACT Sciences’ earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.46). EXACT Sciences reported earnings per share of ($0.23) during the same quarter last year, which would suggest a negative year-over-year growth rate of 82.6%. The business is expected to report its next earnings report on Monday, October 29th.
According to Zacks, analysts expect that EXACT Sciences will report full-year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.52) to ($1.32). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.82) per share, with EPS estimates ranging from ($1.20) to ($0.35). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for EXACT Sciences.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, August 1st. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. EXACT Sciences had a negative return on equity of 20.10% and a negative net margin of 35.24%. The business had revenue of $102.89 million during the quarter, compared to analyst estimates of $104.40 million. During the same period in the prior year, the company earned ($0.27) earnings per share. EXACT Sciences’s revenue was up 78.5% compared to the same quarter last year.
Shares of NASDAQ EXAS opened at $76.28 on Thursday. EXACT Sciences has a 1-year low of $37.36 and a 1-year high of $80.35. The company has a debt-to-equity ratio of 0.87, a quick ratio of 15.37 and a current ratio of 15.79.
In other news, Director Thomas D. Carey sold 3,427 shares of the firm’s stock in a transaction on Monday, July 30th. The stock was sold at an average price of $58.86, for a total value of $201,713.22. Following the completion of the transaction, the director now directly owns 48,983 shares of the company’s stock, valued at $2,883,139.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael S. Wyzga sold 2,468 shares of the firm’s stock in a transaction on Tuesday, August 28th. The stock was sold at an average price of $74.85, for a total value of $184,729.80. Following the completion of the transaction, the director now directly owns 9,112 shares of the company’s stock, valued at $682,033.20. The disclosure for this sale can be found here. Insiders sold 17,014 shares of company stock valued at $1,031,717 over the last ninety days. Corporate insiders own 3.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of EXAS. Asymmetry Capital Management L.P. boosted its stake in EXACT Sciences by 229.2% during the second quarter. Asymmetry Capital Management L.P. now owns 84,937 shares of the medical research company’s stock valued at $5,078,000 after buying an additional 59,134 shares during the period. Swiss National Bank boosted its stake in EXACT Sciences by 1.4% during the second quarter. Swiss National Bank now owns 210,619 shares of the medical research company’s stock valued at $12,593,000 after buying an additional 3,000 shares during the period. Sit Investment Associates Inc. boosted its stake in EXACT Sciences by 24.3% during the second quarter. Sit Investment Associates Inc. now owns 33,300 shares of the medical research company’s stock valued at $1,991,000 after buying an additional 6,500 shares during the period. Hartford Investment Management Co. bought a new stake in EXACT Sciences during the second quarter valued at $202,000. Finally, Formula Growth Ltd. boosted its stake in EXACT Sciences by 30.8% during the second quarter. Formula Growth Ltd. now owns 42,500 shares of the medical research company’s stock valued at $2,541,000 after buying an additional 10,000 shares during the period. 86.40% of the stock is owned by hedge funds and other institutional investors.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Read More: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.